LOCALLY MANUFACTURED AUTOLOGOUS CD19 CHIMERIC ANTIGEN RECEPTOR-T (CAR-T) CELLS FOR PHASE II PROSPECTIVE CLINICAL TRIAL FOR RELAPSED/REFRACTORY B-ACUTE LYMPHOBLASTIC LEUKAEMIA IN MALAYSIA

被引：0
|
作者：
Lim, T. S. [1 ]
Nyunt, W. [1 ]
Then, K. [2 ]
Cheong, S. [2 ]
Then, K. [2 ]
Ooi, G. [2 ]
Govindasamy, V. [2 ]
Idris, M. Mohd [3 ]
Azura, S. [3 ]
Abdullah, N. [3 ]
Zakaria, M. Muhd [3 ,4 ]
Chang, A. H. [6 ]
Ithnin, A. [7 ]
Wahid, S. S. Abdul [3 ,5 ]
机构：
[1] Plutonet Sdn Bhd, Cyberjaya, Malaysia
[2] Cryocord Sdn Bhd, Cyberjaya, Malaysia
[3] Hosp Canselor Tuanku Muhriz Univ Kebangsaan Malay, Pusat Terapi Sel PTS, Kuala Lumpur, Malaysia
[4] Prince Court Med Ctr, Kuala Lumpur, Malaysia
[5] Hosp Canselor Tuanku Muhriz Univ Kebangsaan Malay, Dept Med, Fac Med, Kuala Lumpur, Malaysia
[6] Shanghai YaKe Biotechnol Ltd, Shanghai, Peoples R China
[7] Hosp Canselor Tuanku Muhriz Univ Kebangsaan Malay, Dept Pathol, Kuala Lumpur, Malaysia
来源：
CYTOTHERAPY | 2023年 / 25卷 / 06期
关键词：
CAR-T therapy; CAR-T manufacturing;
D O I：
暂无
中图分类号：
Q813 [细胞工程];
学科分类号：
摘要：
1028
引用
收藏
页码：S225 / S226
页数：2
相关论文
共 50 条
  • [31] Automated Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells at an Academic Center for a Phase I Clinical Trial in Relapsed, Refractory NHL
    Zhu, Fenlu
    Shah, Nirav N.
    Schneider, Dina
    Xu, Huiqing
    Chaney, Katherine
    Luib, Lawrence
    Keever-Taylor, Carolyn
    Dropulic, Boro
    Orentas, Rimas
    Hari, Parameswaran
    Johnson, Bryon D.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [32] Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial
    Wang, Lixin
    Fang, Chuling
    Kang, Qingzheng
    Huang, Wenfa
    Chen, Ziren
    Zhao, Weiqiang
    Wang, Lei
    Wang, Yiran
    Tan, Kun
    Guo, Xiao
    Xu, Yuanyuan
    Wang, Shuhong
    Wang, Lijun
    Qiao, Jingqiao
    Tang, Zhixiong
    Yu, Chuan
    Xu, Yang
    Li, Yisheng
    Yu, Li
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [33] Clinical Validation of Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of B Neoplasia
    Kerbauy, Lucila
    Coa, Larissa Leggieri
    Sielski, Micheli Severo
    Preto Godoy, Juliana Aparecida
    Kondo, Andrea Tiemi
    Cottas Azevedo, Julia Teixeira
    Barbosa, Augusto
    Okamoto, Oswaldo Keith
    Kutner, Jose Mauro
    Hamerschlak, Nelson
    Alves Paiva, Raquel de Melo
    BLOOD, 2022, 140 : 4930 - 4930
  • [34] Phase 1 Results of CNCT19: CD19 CAR Constructed of a New Anti-CD19 Chimeric Antigen Receptor in Relapsed or Refractory Acute Lymphoblastic Leukemia
    Gu, Runxia
    Liu, Fang
    Zou, Dehui
    Liu, Bingcheng
    Liu, Wei
    Chen, Xiaojuan
    Liu, Kaiqi
    Guo, Ye
    Gong, Xiaoyuan
    Lv, Rui
    Chen, Xia
    Zhou, Chunlin
    Zhong, Mengjun
    Xu, Yingxi
    Wang, Huijun
    Wei, Hui
    Mi, Yingchang
    Qiu, Lugui
    Lv, Lulu
    Wang, Min
    Wang, Ying
    Zhu, Xiaofan
    Wang, Jianxiang
    BLOOD, 2019, 134
  • [35] Anti-CD21 Chimeric Antigen Receptor (CAR)-T Cells for T Cell Acute Lymphoblastic Leukaemia (T-ALL)
    Maciocia, Nicola C.
    Burley, Amy
    Nannini, Francesco
    Wawrzyniecka, Patrycja
    Neves, Margarida
    Karpanasamy, Thaneswari
    Ferrari, Mathieu
    Marafioti, Teresa
    Onuoha, Shimobi
    Khwaja, Asim
    Maciocia, Paul M.
    Pule, Martin
    BLOOD, 2021, 138
  • [36] PHASE 1 CLINICAL TRIAL OF CD19 CAR-T CELLS MANUFACTURED AT THE POINT OF CARE USING THE MILTENYI CLINIMACS PRODIGY®
    Hutchins, C. J.
    Henderson, A.
    Lynam, E. C.
    Harvey, K. J.
    Leung, C. W.
    Acworth, M.
    Barnes, E.
    McLean, A. M.
    O'Donnell, M. K.
    Fuery, M.
    Western, R.
    Mudie, K.
    McEnroe, B.
    Henden, A.
    Kennedy, G.
    Tey, S.
    CYTOTHERAPY, 2022, 24 (05) : S134 - S135
  • [37] Phase I Clinical Trial of CD19 CAR-T Cells Expressing CXCR5 Protein for the Treatment of Relapsed or Refractory B-cell Lymphoma
    Wang, Jiaxi
    Jiang, Yirong
    Luo, Min
    Lu, Wenyi
    He, Jixiang
    Zhang, Meng
    Yao, Zhuoxin
    Jin, Xin
    Xiao, Xia
    Chen, Jianhang
    Li, Guangchao
    Ding, Wen
    Zhou, Jie
    Zhang, Zhiyin
    Zhao, Mingfeng
    CURRENT CANCER DRUG TARGETS, 2024,
  • [38] CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives
    Mohty, Mohamad
    Gautier, Jordan
    Malard, Florent
    Aljurf, Mahmoud
    Bazarbachi, Ali
    Chabannon, Christian
    Kharfan-Dabaja, Mohamed A.
    Savani, Bipin N.
    Huang, He
    Kenderian, Saad
    Nagler, Arnon
    Perales, Miguel-Angel
    LEUKEMIA, 2019, 33 (12) : 2767 - 2778
  • [39] Correlative study on the efficacy and complications of CD19 chimeric antigen receptor T cells in the treatment of recurrent/refractory acute lymphoblastic leukemia
    Wen, W.
    Xiaoling, G.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1728 - 1728
  • [40] Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
    Guoqing Wei
    Lijuan Ding
    Jiasheng Wang
    Yongxian Hu
    He Huang
    Experimental Hematology & Oncology, 6
12345